4059 Serpins
Ligands and drugs
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.
The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.
| Superclass | Proteins | Expected | 0.25×observed / expected4× | Ratio | Significance |
|---|---|---|---|---|---|
| Organic oxygen compounds | 15 | 6.5 | 2.31× | q = 1.7e-3 | |
| Homogeneous non-metal compounds | 11 | 7.0 | 1.57× | q = 0.14 | |
| Homogeneous metal compounds | 15 | 16.0 | 0.94× | q = 0.91 | |
| Organoheterocyclic compounds | 4 | 5.0 | 0.80× | q = 0.87 | |
| Organic acids and derivatives | 4 | 5.0 | 0.80× | q = 0.87 | |
| Nucleosides, nucleotides, and analogues | 0 | 9.0 | 0 | q = 1.3e-4 | |
| Organosulfur compounds | 4 | 0.7 | 5.97× | not tested | |
| Phenylpropanoids and polyketides | 1 | 0.7 | 1.48× | not tested | |
| Lipids and lipid-like molecules | 4 | 3.6 | 1.10× | not tested | |
| Organic nitrogen compounds | 1 | 1.0 | 0.96× | not tested | |
| Benzenoids | 2 | 2.4 | 0.84× | not tested |
Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB00141 | NAG | N-Acetylglucosamine | 61 |
| DB09130 | — | — | 11 |
| DB00741 | HCY | Hydrocortisone | 10 |
| DB00451 | T44 | Levothyroxine | 6 |
| DB01593 | — | — | 6 |
| DB14487 | — | — | 6 |
| DB00139 | SIN | Succinic acid | 5 |
| DB14533 | — | — | 4 |
| DB00145 | GLY | Glycine | 3 |
| DB00151 | CYS | Cysteine | 3 |
| DB03345 | BME | Mercaptoethanol | 3 |
| DB05961 | — | PPL-100 | 3 |
| DB00254 | DXT | Doxycycline | 2 |
| DB00997 | DM2 | Doxorubicin | 2 |
| DB03109 | NAA | 2-acetylamino-2-deoxy-b-D-allopyranose | 2 |
| DB03740 | NDG | N-acetyl-alpha-D-glucosamine | 2 |
| DB00197 | — | — | 1 |
| DB00328 | IMN | Indomethacin | 1 |
| DB00396 | STR | Progesterone | 1 |
| DB00481 | — | Raloxifene | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| NAG | 2-acetamido-2-deoxy-beta-D-glucopyranose | 57 |
| CL | CHLORIDE ION | 29 |
| HCY | (11alpha,14beta)-11,17,21-trihydroxypregn-4-ene-3,20-dione | 12 |
| ZNmetal | ZINC ION | 12 |
| NAmetal | SODIUM ION | 11 |
| CAmetal | CALCIUM ION | 9 |
| IOD | IODIDE ION | 7 |
| T44 | 3,5,3',5'-TETRAIODO-L-THYRONINE | 6 |
| MGmetal | MAGNESIUM ION | 5 |
| SIN | SUCCINIC ACID | 5 |
| CYS | CYSTEINE | 4 |
| DM2 | DOXORUBICIN | 4 |
| DXT | (4S,4AR,5S,5AR,6R,12AS)-4-(DIMETHYLAMINO)-3,5,10,12,12A-PENTAHYDROXY-6-METHYL-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE | 4 |
| GLY | GLYCINE | 4 |
| NDG | 2-acetamido-2-deoxy-alpha-D-glucopyranose | 4 |
| STR | PROGESTERONE | 4 |
| 96P | (2S)-3-({[3-(trifluoromethyl)phenoxy]carbonyl}amino)propane-1,2-diyl bis(3,4,5-trihydroxybenzoate) | 3 |
| BME | BETA-MERCAPTOETHANOL | 3 |
| TB7 | TERT-BUTYL 3-[(4-OXO-3H-PYRIDO[2,3-D]PYRIMIDIN-2-YL)AMINO]AZETIDINE-1-CARBOXYLATE | 3 |
| 144 | TRIS-HYDROXYMETHYL-METHYL-AMMONIUM | 2 |